id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-318319-efqf5e1i	Yamasaki, Yukitaka	The peripheral lymphocyte count as a predictor of severe COVID-19 and the effect of treatment with ciclesonide	2020-07-03		.txt	text/plain	2136	144	59	The lymphocyte count after ciclesonide treatment in the non-severe pneumonia group was significantly higher (p = 0. Many patients with coronavirus infection disease 2019(COVID-19) are subclinical, and it has been reported that people are J o u r n a l P r e -p r o o f contagious even when asymptomatic [1, 2] , which means preventing the spread of SARS-CoV-2 is challenging [3] . Risk factors of severe pneumonia include age, comorbidities, smoking, reduced lymphocyte count, elevated ferritin levels, and elevated C-reactive protein (CRP) levels [4] [5] [6] [7] [8] [9] . In addition, we examined whether ciclesonide could prevent the development of severe COVID-19 among patients with these predictors. Moreover, the lymphocyte count after ciclesonide therapy in the non-severe pneumonia group was significantly higher (p=0.0156) compared to before treatment (mean 6.14 days, SD 2.17) (Figure 3b ).	./cache/cord-318319-efqf5e1i.txt	./txt/cord-318319-efqf5e1i.txt